Literature DB >> 18845832

Comparison of three enzyme-linked immunosorbent assays for detection of immunoglobulin g antibodies to tetanus toxoid with reference standards and the impact on clinical practice.

Karen H van Hoeven1, Connie Dale, Phil Foster, Barbara Body.   

Abstract

Accurate determination of the concentrations of immunoglobulin G (IgG) antibody to tetanus toxoid is important in order to evaluate the immunogenicity of tetanus toxoid vaccines, determine immune competence in individual patients, and measure the prevalence of immunity in populations. The performance of three commercially available enzyme-linked immunosorbent assays (ELISAs) for IgG antibodies to tetanus toxoid were evaluated. Serially diluted NIBSC 76/589 and TE-3 human tetanus IgG immunoglobulin international reference standards were analyzed in quadruplicate using ELISAs manufactured by The Binding Site, Inc. (VaccZyme); Scimedx; and Euroimmun. In addition, IgG antibodies to tetanus toxoid were measured in 83 deidentified serum specimens using each manufacturer's ELISA. Each ELISA provided linear results when evaluated with the reference preparations. The Binding Site ELISA provided results that closely corresponded to the reference preparations (y=1.09x-0.08), whereas the Scimedx ELISA gave results that were consistently lower (y=0.21x-0.07) and the Euroimmun ELISA gave results that were consistently higher (y=1.5x+0.30) than the reference preparation concentrations. Using the recommended cutoff for each ELISA (<0.10 IU/ml), the overall agreement of all of the ELISA methods was 78%. Three of eighty-three (3.6%) human serum samples demonstrated inadequate immunity with all three assays. The Binding Site ELISA yielded nonprotective antibody concentrations in only these 3 samples, whereas 19 samples (22.9%) according to the Scimedx ELISA and 6 samples (7.2%) according to the Euroimmun ELISA demonstrated nonprotective concentrations. The performance characteristics of ELISAs for tetanus immunoglobulin titers were manufacturer dependent, and the differences translated into important disparities in reported results.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18845832      PMCID: PMC2593177          DOI: 10.1128/CVI.00254-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  9 in total

1.  Tetanus in a renal transplant recipient exhibiting the presence of circulating antitetanus antibodies determined by ELISA.

Authors:  A de La Chapelle; O Lavabre; M Pinsard; J Delamonica; E H Relyveld
Journal:  Biomed Pharmacother       Date:  2002-06       Impact factor: 6.529

2.  Practice parameter for the diagnosis and management of primary immunodeficiency.

Authors:  Francisco A Bonilla; I Leonard Bernstein; David A Khan; Zuhair K Ballas; Javier Chinen; Michael M Frank; Lisa J Kobrynski; Arnold I Levinson; Bruce Mazer; Robert P Nelson; Jordan S Orange; John M Routes; William T Shearer; Ricardo U Sorensen
Journal:  Ann Allergy Asthma Immunol       Date:  2005-05       Impact factor: 6.347

3.  Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.

Authors:  Emmanuel Grimprel; Frank von Sonnenburg; Roland Sänger; Veronique Abitbol; Joanne M Wolter; Lode M Schuerman
Journal:  Vaccine       Date:  2005-05-25       Impact factor: 3.641

4.  Immunologic response to a single dose of tetanus toxoid in older people.

Authors:  T Shohat; E Marva; Y Sivan; I Lerman; A Mates; A Cohen
Journal:  J Am Geriatr Soc       Date:  2000-08       Impact factor: 5.562

5.  Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.

Authors:  Katrina Kretsinger; Karen R Broder; Margaret M Cortese; M Patricia Joyce; Ismael Ortega-Sanchez; Grace M Lee; Tejpratap Tiwari; Amanda C Cohn; Barbara A Slade; John K Iskander; Christina M Mijalski; Kristin H Brown; Trudy V Murphy
Journal:  MMWR Recomm Rep       Date:  2006-12-15

6.  Immediate allergy to tetanus toxoid vaccine: determination of immunoglobulin E and immunoglobulin G antibodies to allergenic proteins.

Authors:  Cristobalina Mayorga; M José Torres; José Luis Corzo; Javier Alvarez; José Antonio Cornejo García; Cristina Antúnez Rodríguez; Miguel Blanca; Antonio Jurado
Journal:  Ann Allergy Asthma Immunol       Date:  2003-02       Impact factor: 6.347

7.  Immunologic response to tetanus toxoid in the elderly: one-year follow-up.

Authors:  K Alagappan; W Rennie; D Lin; C Auerbach
Journal:  Ann Emerg Med       Date:  1998-08       Impact factor: 5.721

8.  The First International Standard for Antitetanus Immunoglobulin, Human; pharmaceutical evaluation and international collaborative study.

Authors:  D Sesardic; M Y Wong; R E Gaines Das; M J Corbel
Journal:  Biologicals       Date:  1993-03       Impact factor: 1.856

9.  Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Karen R Broder; Margaret M Cortese; John K Iskander; Katrina Kretsinger; Barbara A Slade; Kristin H Brown; Christina M Mijalski; Tejpratap Tiwari; Emily J Weston; Amanda C Cohn; Pamela U Srivastava; John S Moran; Benjamin Schwartz; Trudy V Murphy
Journal:  MMWR Recomm Rep       Date:  2006-03-24
  9 in total
  4 in total

1.  Comparison of five commercial anti-tetanus toxoid immunoglobulin G enzyme-linked immunosorbent assays.

Authors:  A L Perry; A J Hayes; H A Cox; F Alcock; A R Parker
Journal:  Clin Vaccine Immunol       Date:  2009-09-30

2.  Serum anti-tetanus and measles antibody titres in Ugandan children aged 4 months to 6 years: implications for vaccine programme.

Authors:  Lenesha Warrener; Josephine Bwogi; Nick Andrews; Dhanraj Samuel; Theopista Kabaliisa; Henry Bukenya; Kevin Brown; Martha H Roper; David A Featherstone; David Brown
Journal:  Epidemiol Infect       Date:  2018-05-09       Impact factor: 4.434

3.  Expression of recombinant antibodies.

Authors:  André Frenzel; Michael Hust; Thomas Schirrmann
Journal:  Front Immunol       Date:  2013-07-29       Impact factor: 7.561

4.  The Influence of Moisture Content and Temperature on the Long-Term Storage Stability of Freeze-Dried High Concentration Immunoglobulin G (IgG).

Authors:  Arnold Duralliu; Paul Matejtschuk; Paul Stickings; Laura Hassall; Robert Tierney; Daryl R Williams
Journal:  Pharmaceutics       Date:  2020-03-27       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.